Osicent (Osimertinib) 80 mg

Osicent 80 mg is the Bangladeshi version of osimertinib. It is formulated with the original formula. Original tagrisso and Bangladesh made Osicent work the same. Not only that, Bangladeshi Tagrix costs about 70℅ less than the original Tagrisso but can deliver the same results. Incepta Pharma manufactures Osicen-80.

The USFDA approved Osicen as the first drug of its kind to treat Non- Small Cell Lung Cancer patients.

FAQ About Osicent 80

Q: What kind of drug is osimertinib?

Osimertinib belongs to the group of medicines called antineoplastic (cancer medicines). The treatment interferes with the growth of cancer cells, eventually destroying them.

Q: Is Osicent a form of chemotherapy?

No, Osicent is not chemotherapy, but targeted therapy. Targeted therapies work differently than traditional chemotherapy. Chemotherapy kills rapidly dividing cells and can affect many types of cells in the body, including healthy cells.

Q: Is Osicent a targeted therapy?

(Osicent ^®) is a targeted therapy drug. Doctors use it to treat non-small cell lung cancer.

Q: How effective is Osicent?

Osicent 80 reduced the risk of disease recurrence or death by 79%). Osicent was associated with superior DFS rates at 1 (97% vs 69%), 2 (89% vs 53%), and 3 years (79% vs 41%). The cancer drug (Tagrisso) improves survival in people with non-small cell lung cancer with EGFR mutations,

Q: Who invented this drug?

Osicent (previously known as mereletinib or AZD9291, trade name Tagrisso) is a third-generation drug developed by AstraZeneca Pharmaceuticals for mutated EGFR cancers.

Q: What is the cost of this medicine?

In the U.S., this medicine costs $17,028.90 per month, compared erlotinib (Tarceva, Genentech) at $9,390.44, gefitinib (Iressa, AstraZeneca) at $9,117.36 and afatinib (Gilotrif, Boehringer Ingelheim) at $9,785.72. In the Bangladeshi version of Osicent Price is around $150 to $300 for 30 Tablets. before your order check our Terms & Condition

Use in Pregnancy & Lactation: Osicent can cause fetal harm when administered to a pregnant woman. There are no available data on Osicent use in pregnant women.

Lactation: There are no data on the presence of Osicent in human milk. The effects of Osicent on the breastfed infant, or milk production.

Overdose: If an overdose occurs the patient must be monitored for evidence of toxicity. Treatment of overdose includes monitoring of vital signs as well as observation of the clinical status of the patient.

Storage Store: in a cool and dry place, away from light. Keep out of the reach of children.